Liberty Health Sciences (CSE: LHS) (OTCQX: LHSIF) - Investor Dashboard

➔ Liberty Health Sciences
CSE Ticker: LHS
Market Focus: United States
Classification: Vertically Integrated
Country: United States
Employees: 220 as of 07/02/19
Established: 2017
Interim CEO: Victor E. Mancebo


Fiscal Year-End: February
Auditor: MNP
Licenses: FL, OH, and MA
Licensed Capacity:  Not limited
Number of Patients: ~14,500 (12/2018)
Headquarters: Toronto, ON

Financials (As of 08/31/19)

Cash on hand: C$23.9 million
Fixed Investment: C$69.5million
Shareholders’ Equity: C$134.0 million
Revenues – Last Quarter: C$10.4 million
Adj. Gross Margin : 47.1%
EPS : 0.07

Capital Structure (As of 10/30/19)

Last Financing: $23mm Units at C$0.90
Basic Shares: 345.3mm
Warrants: 33.0mm
Options: 12.4mm
Diluted Shares: 396.7mm

Company Brief

Liberty Health Sciences is one of the first Canadian cannabis companies to focus on cultivation and distribution in the U.S. market. They launched their American expansion in the state of Florida and currently operates and manages one of thirteen licenses in that state which has a population of over 20 million people.

Liberty has a strong balance sheet with available cash and no debt and an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. The company is committed to delivering high-quality, clean and safe pharma-grade cannabis to patients while optimizing returns to shareholders.

Liberty Health Sciences Site Tour


  • Well-capitalized balance sheet with access to capital to fund growth
  • Seed-to-sale certified with quality control exceeding industry standards
  • Liberty 360° Campus in Gainesville, Florida provides significant production capacity
  • Florida medical cannabis sales license, Massachusetts medical license, and Ohio dispensary
  • Exclusive licensing agreements with MM Technology Holdings (Mary’s Medicinals) in Florida and Massachusetts, MC Brands (Incredibles) in Florida, and Isodiol International in Florida and Massachusetts


  • Management team and board of directors with substantial skin-in-the-game via ownership of shares
  • Committed to delivering high-quality, clean and safe pharmaceutical grade cannabis to American patients
  • Three Florida delivery hubs: Ft. Lauderdale, St. Petes, and Tallahassee
  • 24-hour state-wide delivery in Florida

Growth Strategy

  • Entry will be prioritized into states with large populations, multiple approved conditions, and no canopy restrictions
  • Vertical license applications in Michigan and New Jersey
  • Liberty 360° Campus to reach commercial production by early 2019
  • Plans for 15 to 18 dispensaries by 2020
  • Florida dispensary additions: Click here to view

Institutional Analyst Coverage

Clarus Securities

Curated Stories & News

Visit Liberty Health Sciences Inc.,

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Liberty Health Sciences, Inc. is a client of NCV Media, LLC. Read our full disclaimer.